Opexa Therapeutics, Inc., a drug delivery company based in The Woodlands, Texas, has been making significant progress in researching and developing Tcelna®, a breakthrough T-cell immunotherapy for multiple sclerosis (MS). The company recently announced they have reached their enrollment mark for conducting a Phase IIb clinical trial to test Tcelna as a viable…
SPMS
Recommended Posts
- MS causing fewer deaths, less disability than in the past: Study
- Living with MS migraines and navigating the ‘prior authorization’ trap
- Briumvi outperforms Aubagio in highly active relapsing MS: Study
- How I ‘keep moving’ in life with MS
- MS patients about twice as likely to have restless legs syndrome: Study